Specialties – Page 22

No Time to Waste: Addressing Diagnostic Delays in Vulvar Squamous Cell Carcinoma

By MedXY 08/25/2026

This article reviews a study identifying key factors contributing to delays in diagnosing vulvar squamous cell carcinoma, emphasizing provider and system-level influences and the need for timely biopsy and specialist referrals.

Hematology-Oncology news OB/GYN & Women’s Health

Oral Anticoagulation Significantly Lowers Venous Thromboembolism Rates in Ovarian Cancer Patients on First-Line Chemotherapy: Insights from a Quality Improvement Project

By MedXY 08/25/2026

A quality improvement initiative integrating oral anticoagulants reduced venous thromboembolism incidence in ovarian cancer patients undergoing first-line chemotherapy without increasing bleeding risks.

Neurology news Pediatrics

Early Escalation of Acute Treatment Reduces Relapse Risk in Pediatric MOG Antibody-Associated Disease

By MedXY 08/25/2026

In pediatric myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), escalation of acute immunotherapy beyond steroids at first attack is linked to significantly fewer relapses within one year and mid-term follow-up, highlighting a critical therapeutic window to alter disease trajectory.

Neurology news Public Health

Lifelong Risk of De Novo Aneurysm Formation in Young Survivors of Aneurysmal Subarachnoid Hemorrhage: A Four-Decade Perspective

By MedXY 08/25/2026

Young survivors of aneurysmal subarachnoid hemorrhage face a lifelong risk of developing new aneurysms, with female sex, smoking, and family history as key risk factors. Smoking cessation reduces this risk, supporting need for lifelong surveillance.

Diabetes & Endocrinology news OB/GYN & Women’s Health

Pregnancy Following Hemithyroidectomy: Elevated Risk of Gestational Overt Hypothyroidism Amid Favorable Obstetric Outcomes

By MedXY 08/25/2026

Women with preconception hemithyroidectomy face a substantially increased risk of overt hypothyroidism during pregnancy, especially after thyroid cancer surgery, yet obstetric outcomes remain comparable to women with intact thyroids.

Diabetes & Endocrinology news Oncology

Accelerating Radioiodine Therapy in Differentiated Thyroid Cancer: A Novel 24-Hour Diagnostic 131I Scan Protocol Post-rhTSH Administration

By MedXY 08/25/2026

A novel protocol performing diagnostic 131I scans within 24 hours after the second rhTSH injection reliably guides radioiodine therapy in differentiated thyroid cancer, enabling same-cycle pre-treatment evaluation and treatment without schedule alteration.

Diabetes & Endocrinology news

Coordinated Precision Care for Rare Genetic Obesity: European Expert Consensus on Centers of Expertise and Structured Monitoring

By MedXY 08/25/2026

European experts recommend designated centers, structured diagnostic pathways, and real‑world monitoring to deliver precision therapies (MC4R agonists) safely and equitably to people with rare genetic forms of obesity.

Diabetes & Endocrinology Gastroenterology news

Reevaluating the Link Between Helicobacter pylori Infection and Insulin Resistance: Insights from Frequentist and Bayesian Analyses in a European Cohort

By MedXY 08/25/2026

A comprehensive European cohort study reveals that Helicobacter pylori infection's association with insulin resistance is confounded by socioeconomic and lifestyle factors, arguing against its independent causal role and the need for eradication to prevent metabolic syndrome.

Diabetes & Endocrinology news Pediatrics

Fecal Short-Chain Fatty Acids in Mother-Infant Dyads: No Direct Link to Islet Autoimmunity Development

By MedXY 08/25/2026

A longitudinal study shows no association between fecal short-chain fatty acid levels during pregnancy and early childhood with the progression to islet autoimmunity in children at risk for type 1 diabetes.

Diabetes & Endocrinology news

HTD1801 Monotherapy Significantly Improves Glycemic Control and Cardiometabolic Health in Type 2 Diabetes: Results From a 56-Week Phase 3 Trial

By MedXY 08/25/2026

A phase 3 trial demonstrated that HTD1801 monotherapy significantly reduces HbA1c and improves cardiometabolic and inflammatory markers in patients with inadequately controlled type 2 diabetes, with sustained effects and a favorable safety profile over 56 weeks.

Cardiology news

Unraveling Right Ventricular Failure in PH-HFpEF: Integrative Insights from Vascular Mechanics and Transcriptomics

By MedXY 08/25/2026

This study integrates vascular mechanics, advanced imaging, and myocardial transcriptomics to elucidate the mechanisms of right ventricular failure in pulmonary hypertension secondary to heart failure with preserved ejection fraction, uncovering key vascular and molecular remodeling pathways.

Cardiology news

GLI1 Activation in Intermittent Hypoxia: A Novel Mechanistic Link Driving Cardiac Fibrosis in Obstructive Sleep Apnea

By MedXY 08/25/2026

This study reveals that intermittent hypoxia activates GLI1 transcription factor in cardiac fibroblasts, driving fibrosis via PKM2-mediated glycolysis, and highlights GLI1 as a promising therapeutic target in OSA-associated cardiac dysfunction.

Cardiology news

The Second Universal Definition of Heart Failure (2026): What Clinicians and Health Systems Need to Know

By MedXY 08/25/2026

A clear, global update standardizing heart failure terminology, phenotypes, causes, and trajectories to improve prevention, diagnosis, treatment, and global surveillance.

news Oncology Otorhinolaryngology

Enhanced Pathologic Response in Head and Neck Squamous Cell Carcinoma with Neoadjuvant Chemoimmunotherapy

By MedXY 08/25/2026

Neoadjuvant chemoimmunotherapy significantly improves pathologic response rates in resectable head and neck squamous cell carcinoma compared to immunotherapy alone, potentially transforming preoperative treatment strategies.

General Surgery Neurology news

Mapping Cognitive Load in Novice Surgeons: Insights Into Brain Activation and Performance Under Stress

By MedXY 08/25/2026

This study elucidates how escalating cognitive workload affects brain activation in novice surgical residents, revealing distinct neural patterns linked to performance resilience or decline during simulated suturing tasks.

Internal Medicine news Public Health

Randomized Quality Improvement Trials: Enhancing Healthcare Safety with Ethical Oversight

By MedXY 08/24/2026

Randomized Quality Improvement (RQI) trials offer robust evidence for healthcare interventions but raise ethical and regulatory challenges. A proposed framework provides streamlined oversight enabling safer, evidence-based care improvements within health systems.

Hematology-Oncology news

ATG Versus ATG Plus Post-Transplant Cyclophosphamide: A Pilot Trial for GvHD Prophylaxis in Matched Donor Hematopoietic Cell Transplants

By MedXY 08/24/2026

A randomized pilot trial shows comparable survival and safety outcomes for anti-thymocyte globulin alone versus combined with post-transplant cyclophosphamide, supporting further phase III investigation for graft-versus-host disease prophylaxis in matched donor hematopoietic cell transplantation.

Clinical Updates Hematology-Oncology news

Response Kinetics Following CAR T-Cell Therapy for Large B-Cell Lymphoma: Insights from the LYSA DESCAR-T Registry

By MedXY 08/24/2026

This review synthesizes real-world data from the DESCAR-T registry on CAR T-cell therapy response kinetics in large B-cell lymphoma, highlighting the prognostic impact of early response patterns and factors influencing conversion from partial to complete remission.

Hematology-Oncology news

Decoding ATRA Resistance in Acute Promyelocytic Leukemia: The Role of PML::RARA Mutations Enhancing Basal Repression

By MedXY 08/24/2026

A clustered subset of hotspot PML::RARA mutations drives ATRA resistance in acute promyelocytic leukemia by enhancing basal transcriptional repression rather than disrupting transactivation, suggesting novel mechanisms underlying therapeutic failures.

$Enhanced Salvage Therapy in Relapsed/Refractory AML: Venetoclax Plus High-Dose Cytarabine and Mitoxantrone Shows Promising Outcomes and Risk Stratification Insights$

Hematology-Oncology news Oncology

Enhanced Salvage Therapy in Relapsed/Refractory AML: Venetoclax Plus High-Dose Cytarabine and Mitoxantrone Shows Promising Outcomes and Risk Stratification Insights

By MedXY 08/24/2026

A multicenter real-world study demonstrates that combining venetoclax with high-dose cytarabine and mitoxantrone significantly improves remission and survival rates in relapsed/refractory AML, with validated risk factors guiding prognostication.